Sarkis Morales-Vidal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sarkis Morales-Vidal has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Alejandro Hornik
2 shared publicationsChristopher Morgan
2 shared publicationsJosé Biller
2 shared publicationsMichael J Schneck
2 shared publicationsMichael Schneck
2 shared publications- Adolfo Ramirez-Zamora
Department of Neurology University of Louisville Louisville KY USA
1 shared publication
Latest Publications
- 1 August 2013
- Published by Elsevier in Neurologic Clinics
- Vol. 31 (3) , 633-657
Platelet Antiaggregants in Stroke Prevention
- 1 August 2013
- Published by Elsevier in Neurologic Clinics
- Vol. 31 (3) , 633-657
Platelet Antiaggregants in Stroke Prevention
- 1 April 2013
- Published by Taylor & Francis in Hospital Practice
- Vol. 41 (2) , 108-122
Management of Acute Ischemic Stroke
Stroke is one of the most common causes of morbidity and mortality in hospitalized patients in the United States. A proper understanding of stroke mechanisms helps to guide specific case management. The only therapy approved by the US Food and Drug Administration for the management of acute ischemic stroke is initiation of intravenous recombinant tissue plasminogen activator within 3 hours of symptom onset. Other treatment options include intra-arterial recombinant tissue plasminogen activator, mechanical thrombectomy, clot retrieval, or a combination of these approaches. In this article, we provide an evidence-based review of the diagnostic approach for acute ischemic stroke, including recognizing common stroke mimics. We detail the initial medical management of acute stroke and the medical and surgical therapeutic interventions for patients who have sustained acute ischemic stroke.
- 1 April 2013
- Published by Taylor & Francis in Hospital Practice
- Vol. 41 (2) , 108-122
Management of Acute Ischemic Stroke
Stroke is one of the most common causes of morbidity and mortality in hospitalized patients in the United States. A proper understanding of stroke mechanisms helps to guide specific case management. The only therapy approved by the US Food and Drug Administration for the management of acute ischemic stroke is initiation of intravenous recombinant tissue plasminogen activator within 3 hours of symptom onset. Other treatment options include intra-arterial recombinant tissue plasminogen activator, mechanical thrombectomy, clot retrieval, or a combination of these approaches. In this article, we provide an evidence-based review of the diagnostic approach for acute ischemic stroke, including recognizing common stroke mimics. We detail the initial medical management of acute stroke and the medical and surgical therapeutic interventions for patients who have sustained acute ischemic stroke.
- 1 February 2013
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 13 (2) , 167-175
Commonly asked questions in the management of perioperative stroke
Certain surgical interventions increase stroke risk. Perioperative stroke significantly increases perioperative morbidity and mortality. Several interventions, such as perioperative continuation of antithrombotic therapy during selected surgical interventions, may decrease stroke risk without significantly increasing rates of adverse effects. Commonly asked questions in the management of perioperative stroke includes: What are the mechanisms of perioperative stroke? What are the stroke risk factors and perioperative risks? What is the perioperative stroke risk with discontinuation of antithrombotic medications? What risk modifications strategies can be implemented to decrease perioperative stroke risk? What is the role of neuroimaging in the management of perioperative stroke? What is the evidence for the management of perioperative acute ischemic stroke? This article provide an evidence-based review to these questions and comments on potential interventions in the management of these patients.
- 1 February 2013
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 13 (2) , 167-175
Commonly asked questions in the management of perioperative stroke
Certain surgical interventions increase stroke risk. Perioperative stroke significantly increases perioperative morbidity and mortality. Several interventions, such as perioperative continuation of antithrombotic therapy during selected surgical interventions, may decrease stroke risk without significantly increasing rates of adverse effects. Commonly asked questions in the management of perioperative stroke includes: What are the mechanisms of perioperative stroke? What are the stroke risk factors and perioperative risks? What is the perioperative stroke risk with discontinuation of antithrombotic medications? What risk modifications strategies can be implemented to decrease perioperative stroke risk? What is the role of neuroimaging in the management of perioperative stroke? What is the evidence for the management of perioperative acute ischemic stroke? This article provide an evidence-based review to these questions and comments on potential interventions in the management of these patients.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 197
Autopsy Proven Peripheral Nervous System Neurolymphomatosis Despite Negative Bilateral Sural Nerve Biopsy
Neurolymphomatosis (NL) refers to a lymphomatous infiltration of peripheral nerves associated with central nervous system (CNS) or systemic lymphoma, or alternatively, neurodiagnostic evidence of nerve enhancement and/or enlargement beyond the dural sleeve in the setting of primary central nervous system lymphoma (PCNSL) or systemic lymphoma. NL is a rare complication of systemic cancer with heterogeneous clinical presentations and an elusive diagnosis. Diagnosis usually requires the demonstration of infiltrating malignant lymphocytes in the peripheral nerve. Infiltration of brain parenchyma, meninges or Virchow-Robin spaces is characteristic of systemic disease at autopsy. We describe a patient presenting with biopsy negative NL affecting exclusively the peripheral nervous system at autopsy.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 197
Open AccessAutopsy Proven Peripheral Nervous System Neurolymphomatosis Despite Negative Bilateral Sural Nerve Biopsy
Neurolymphomatosis (NL) refers to a lymphomatous infiltration of peripheral nerves associated with central nervous system (CNS) or systemic lymphoma, or alternatively, neurodiagnostic evidence of nerve enhancement and/or enlargement beyond the dural sleeve in the setting of primary central nervous system lymphoma (PCNSL) or systemic lymphoma. NL is a rare complication of systemic cancer with heterogeneous clinical presentations and an elusive diagnosis. Diagnosis usually requires the demonstration of infiltrating malignant lymphocytes in the peripheral nerve. Infiltration of brain parenchyma, meninges or Virchow-Robin spaces is characteristic of systemic disease at autopsy. We describe a patient presenting with biopsy negative NL affecting exclusively the peripheral nervous system at autopsy.
- 3 July 2012
- Published by BMJ in BMJ Case Reports
- Vol. 2012
Cocaine induced hippocampi infarction
A middle age man presented with disorientation and memory impairment due to bilateral hippocampal strokes secondary to cocaine use. This is the second report of cocaine induced hippocampi ischaemic strokes. In contrast to the previous report, this middle age man did not have cardiac arrest.
- 3 July 2012
- Published by BMJ in BMJ Case Reports
- Vol. 2012
Cocaine induced hippocampi infarction
A middle age man presented with disorientation and memory impairment due to bilateral hippocampal strokes secondary to cocaine use. This is the second report of cocaine induced hippocampi ischaemic strokes. In contrast to the previous report, this middle age man did not have cardiac arrest.
- 1 July 2012
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 124 (4) , 145-153
Diabetic Peripheral Neuropathy and the Management of Diabetic Peripheral Neuropathic Pain
Diabetic peripheral neuropathy (DPN) affects approximately half of patients with diabetes. Neuropathic pain is a major complaint of patients with diabetic polyneuropathy. Diabetic peripheral neuropathy can also lead to autonomic dysfunction. This article provides an outline of the clinical subtypes, pathophysiological features, and diagnosis of DPN. Disease–modifying treatments are reviewed, with particular attention paid to DPN pain management.
- 1 July 2012
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 124 (4) , 145-153
Diabetic Peripheral Neuropathy and the Management of Diabetic Peripheral Neuropathic Pain
Diabetic peripheral neuropathy (DPN) affects approximately half of patients with diabetes. Neuropathic pain is a major complaint of patients with diabetic polyneuropathy. Diabetic peripheral neuropathy can also lead to autonomic dysfunction. This article provides an outline of the clinical subtypes, pathophysiological features, and diagnosis of DPN. Disease–modifying treatments are reviewed, with particular attention paid to DPN pain management.
- 1 February 2012
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 12 (2) , 179-190
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease
Stroke is a leading cause of cardiovascular morbidity and mortality worldwide. Approximately, 795,000 strokes occur in the USA each year, 610,000 of which are first events, and 185,000 of which are recurrent events. Of all strokes, 87% are ischemic strokes. Novel anticoagulants serve as an alternative antithrombotic intervention in patients with ischemic cerebrovascular disease. This paper reviews the role of the novel anticoagulants, dabigatran, rivaroxaban and apixaban, in stroke prevention among patients with nonvalvular atrial fibrillation.
- 1 February 2012
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 12 (2) , 179-190
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease
Stroke is a leading cause of cardiovascular morbidity and mortality worldwide. Approximately, 795,000 strokes occur in the USA each year, 610,000 of which are first events, and 185,000 of which are recurrent events. Of all strokes, 87% are ischemic strokes. Novel anticoagulants serve as an alternative antithrombotic intervention in patients with ischemic cerebrovascular disease. This paper reviews the role of the novel anticoagulants, dabigatran, rivaroxaban and apixaban, in stroke prevention among patients with nonvalvular atrial fibrillation.
- Open Access
- 1 May 2011
- Published by SAGE Publications in Women's Health
- Vol. 7 (3) , 283-292
Stroke- and Pregnancy-Induced Hypertensive Syndromes
Pregnancy-induced hypertensive syndromes are an important cause of cerebrovascular diseases during pregnancy. Women with pregnancy-induced hypertensive syndromes are at an increased risk of ischemic and hemorrhagic strokes. Posterior reversible encephalopathy and reversible vasoconstriction syndromes are common. Cerebral venous sinus thrombosis may also occur. Preeclampsia and eclampsia reflect generalized endothelial dysfunction. Prompt diagnosis and identification of patients at risk allows for early therapeutic interventions and improved clinical outcomes.
- 1 May 2011
- Published by SAGE Publications in Women's Health
- Vol. 7 (3) , 283-292
Open AccessStroke- and Pregnancy-Induced Hypertensive Syndromes
Pregnancy-induced hypertensive syndromes are an important cause of cerebrovascular diseases during pregnancy. Women with pregnancy-induced hypertensive syndromes are at an increased risk of ischemic and hemorrhagic strokes. Posterior reversible encephalopathy and reversible vasoconstriction syndromes are common. Cerebral venous sinus thrombosis may also occur. Preeclampsia and eclampsia reflect generalized endothelial dysfunction. Prompt diagnosis and identification of patients at risk allows for early therapeutic interventions and improved clinical outcomes.